Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 390

Gastroenterology

  • Home
  • Gastroenterology
Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study
Condition:   Diabetic Gastroparesis
Intervention:   Device: Thoracic Splanchnic Magnetic Neuromodulation Therapy
Sponsors:   Augusta University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 14, 2021 / by / in
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Conditions:   HER2-positive Breast Cancer;   HER2 Gene Mutation;   HER-2 Gene Amplification;   HER2 Positive Gastric Cancer;   Salivary Gland Cancer;   Salivary Gland Tumor;   Salivary Gland Carcinoma;   Salivary Gland Neoplasms;   Lung Cancer;   Colo-rectal Cancer;   Rare Diseases;   Solid Tumor;   Recurrent Gastric Cancer;   Recurrent Colon Cancer;   Recurrent Breast Cancer;   Head and Neck Cancer;   Head and Neck Carcinoma;   Bladder Cancer;   Cervical Cancer;   Liver Cancer;   Bile Duct Cancer;   Urologic Cancer;   Pancreatic Cancer;   Prostate Cancer;   Recurrent Prostate Cancer;   Rectal Cancer;   Recurrent Ovarian Carcinoma;   Recurrent Renal Cell Cancer;   Rectal Cancer Stage II;   Rectal Cancer Stage I;   Rectal Cancer Stage III;   Skin Cancer;   Mouth Cancer;   Lip Cancer Stage I;   Tongue Cancer;   Breast Neoplasm Malignant Primary;   Larynx Cancer;   Tonsil Cancer;   Palate Cancer;   Mucoepidermoid Carcinoma;   Primary Peritoneal Carcinoma;   Mucinous Adenocarcinoma Gastric;   Mucinous Breast Cancer Recurrent;   Cholangiocarcinoma
Intervention:   Drug: A166
Sponsor:   Klus Pharma Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 13, 2021 / by / in
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Conditions:   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Malignant Uterine Neoplasm;   Metastatic Colorectal Carcinoma;   Metastatic Gastric Carcinoma;   Metastatic Malignant Neoplasm in the Peritoneum;   Metastatic Ovarian Carcinoma;   Pathologic Stage IV Gastric Cancer AJCC v8;   Peritoneal Carcinomatosis;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8;   Stage IIIA Ovarian Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIA Endometrial Cancer;   Stage IIIB Endometrial Cancer;   Stage IIIC Endometrial Cancer;   Appendiceal Cancer
Interventions:   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Fluorouracil;   Procedure: Intraperitoneal Chemotherapy;   Drug: Leucovorin;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Device: Nebulizer with High-Pressure Injector
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 12, 2021 / by / in
Compassionate Use of Domperidone for Refractory Gastroparesis
Conditions:   GERD;   Gastroesophageal Reflux;   Gastroparesis
Intervention:   Drug: Domperidone
Sponsor:   Children’s Mercy Hospital Kansas City
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 8, 2021 / by / in
GEBT Telehealth Administration Usability Study
Condition:   Gastroparesis
Intervention:   Device: GEBT Telehealth Administration Usability
Sponsor:   Cairn Diagnostics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 29, 2020 / by / in
Study of CRX100 in Patients With Advanced Solid Tumors
Conditions:   Solid Tumor, Adult;   Triple Negative Breast Cancer;   Colorectal Cancer;   Hepatocellular Carcinoma;   Osteosarcoma;   Epithelial Ovarian Cancer;   Gastric Cancer
Intervention:   Biological: CRX100 suspension for infusion
Sponsor:   BioEclipse Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 22, 2020 / by / in
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Conditions:   Gastric Cancer;   Gastric Neoplasm;   Gastrointestinal Stromal Sarcoma;   Gastrointestinal Stromal Neoplasm;   Gastrointestinal Stromal Tumor (GIST)
Intervention:  
Sponsor:   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 22, 2020 / by / in
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
Condition:   Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)
Interventions:   Drug: NT-17;   Drug: Nivolumab
Sponsors:   NeoImmuneTech;   Bristol-Myers Squibb
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 18, 2020 / by / in
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Conditions:   Bladder Cancer;   Head and Neck Squamous Cell Carcinoma;   Cancer of the Salivary Gland;   Lung Cancer;   Breast Cancer;   Gastric Cancer;   Esophageal Cancer;   Colorectal Cancer;   Pancreatic Adenocarcinoma;   Solid Tumor
Intervention:   Biological: CAdVEC
Sponsors:   Baylor College of Medicine;   The Methodist Hospital System
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 18, 2020 / by / in
Rare Disease Patient Registry & Natural History Study – Coordination of Rare Diseases at Sanford
Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia – Renal Agenesis – Psychomotor Retardation;   Aniridia – Ptosis – Intellectual Disability – Familial Obesity;   Aniridia – Cerebellar Ataxia – Intellectual Disability;   Aniridia – Absent Patella;   Aniridia;   Peters Anomaly – Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability – Ataxia – Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia – Unknown;   Spinocerebellar Ataxia – Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia – Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia – Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy – Hearing Loss – Ataxia – Retinitis Pigmentosa – Cataract;   Muscular Atrophy – Ataxia – Retinitis Pigmentosa – Diabetes Mellitus;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy – Deafness;   NARP Syndrome;   Myoclonus – Cerebellar Ataxia – Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Leigh Syndrome;   Late-onset Ataxia With Dementia;   Infection or Post Infection Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration – Blindness – Ataxia – Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract – Ataxia – Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia – Hypogonadism;   Cerebellar Ataxia – Ectodermal Dysplasia;   Cerebellar Ataxia – Areflexia – Pes Cavus – Optic Atrophy – Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly – Nystagmus – Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia – Optic Atrophy – Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia – Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia – Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia – Blindness – Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia – Oculomotor Apraxia Type 1;   Ataxia – Other;   Ataxia – Genetic Diagnosis – Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet’s Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie;   VCP Disease;   Hypnic Jerking;   Sleep Myoclonus;   Mollaret Meningitis;   Recurrent Viral Meningitis;   CRB1;   Leber Congenital Amaurosis;   Retinitis Pigmentosa;   Rare Retinal Disorder;   KCNMA1-Channelopathy;   Primary Biliary Cirrhosis;   ZMYND11;   Transient Global Amnesia;   Glycogen Storage Disease;   Alstrom Syndrome;   White Sutton Syndrome;   DNM1;   EIEE31;   Myhre Syndrome;   Recurrent Respiratory Papillomatosis;   Laryngeal Papillomatosis;   Tracheal Papillomatosis;   Refsum Disease;   Nicolaides Baraitser Syndrome;   Leukodystrophy;   Tango2;   Cauda Equina Syndrome;   Rare Gastrointestinal Disorders;   Achalasia-Addisonian Syndrome;   Achalasia Cardia;   Achalasia Icrocephaly Syndrome;   Anal Fistula;   Congenital Sucrase-Isomaltase Deficiency;   Eosinophilic Gastroenteritis;   Idiopathic Gastroparesis;   Hirschsprung Disease;   Rare Inflammatory Bowel Disease;   Intestinal Pseudo-Obstruction;   Scleroderma;   Short Bowel Syndrome;   Sacral Agenesis;   Sacral Agenesis Syndrome;   Caudal Regression;   Scheuermann Disease;   SMC1A Loss of Function Epilepsy
Intervention:  
Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group – NORD;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet’s Disease Association;   Alstrom United Kingdom;   Athymia;   Curing Retinal Blindness Foundation;   HSAN1E Society;   1p36 Deletion Support and Awareness;   The Alagille Syndrome Alliance;   Autoinflammatory Alliance;   Beyond Batten;   Bohring-Opitz Syndrome Foundation, INC;   Cockayne Syndrome Network (Share and Care);   CRMO Foundation;   Cure VCP Disease,INC;   FOD Support;   Cystinosis Research Foundation;   Global DARE Foundation;   Hypnic Jerk-Sleep Myoclonus Support Group;   Jansen’s Foundation;   KCNMA1 Channelopathy International Advocacy Foundation;   Kawasaki Disease Foundation Australia;   Life with LEMS Foundation;   Lowe Syndrome Association;   The Malan Syndrome Foundation;   Maple Syrup Urine Disease Family Support Group;   International Association for Muscle Glycogen Storage Disease (IamGSD);   Myhre Syndrome Foundation;   DNM1 Families;   Nicolaides Baraitser Syndrome (NCBRS) Worldwide Foundation;   The PBCers Organization;   Pitt Hopkins Research Foundation;   Progressive Familial Intrahepatic Cholestasis Advocacy and Resource Network, Inc;   Recurrent Meningitis Association;   Recurrent Respiratory Papillomatosis Foundation;   Remember the Girls;   Smith-Kingsmore Syndrome Foundation;   SPG Research Foundation;   Team Telomere;   Transient Global Amnesia Project;   The Charlotte & Gwenyth Gray Foundation;   The Cute Syndrome Foundation;   The Maddi Foundation;   White Sutton Syndrome Foundation;   Zmynd11 Gene Disorder;   Cauda Equina Foundation, Inc;   Tango2 Research Foundation;   Noah’s Hope – Hope4Bridget Foundation;   Project Sebastian;   SMC1A Epilepsy Foundation;   International Foundation for Gastrointestinal Disorders;   Endosalpingiosis Foundation, Inc;   International Sacral Agenesis/Caudal Regression Association (ISACRA);   Scheuermann’s Disease Fund
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 11, 2020 / by / in